Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: Prognostic significance and relationship with markers for aggressiveness

Histopathology

Volumn 61, Issue 3, 2012, Pages 350-364

  Dhakal, Hari Prasad ^a   Naume, Bjørn ^a,b   Synnestvedt, Marit ^a   Borgen, Elin ^a   Kaaresen, Rolf ^b,c   Schlichting, Ellen ^c   Wiedswang, Gro ^c   Bassarova, Assia ^a   Holm, Ruth ^a   Giercksky, Karl Erik ^a,b   Nesland, Jahn M ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast carcinoma; Disseminated tumour cell; Vascular endothelial growth factor; Vascular endothelial growth factor receptor; Vascularity

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TAMOXIFEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BONE MARROW; BONE MARROW METASTASIS; BREAST CANCER SPECIFIC SURVIVAL; BREAST CARCINOMA; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RISK FACTOR; TISSUE SECTION; TUMOR VASCULARIZATION;

BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84865399077     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04223.x     Document Type: Article

References (48)

1. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl Cancer Inst. 1992; 84; 1875-1887.
2. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J. Pathol. 1995; 177; 275-283.
3. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin. Cancer Res. 2000; 6; 139-146.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003; 9; 669-676.
5. Bando H, Weich HA, Brokelmann M et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br. J. Cancer 2005; 92; 553-561.
6. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br. J. Cancer 2007; 96; 1092-1100.
7. Ghosh S, Sullivan CA, Zerkowski MP et al. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum. Pathol. 2008; 39; 1835-1843.
8. Ludovini V, Sidoni A, Pistola L et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res. Treat. 2003; 81; 159-168.
9. Nieto Y, Woods J, Nawaz F et al. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br. J. Cancer 2007; 97; 391-397.
10. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J. Pathol. 1998; 184; 44-52.
11. Wu Y, Hooper AT, Zhong Z et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int. J. Cancer 2006; 119; 1519-1529.
12. Schmidt M, Voelker HU, Kapp M, Dietl J, Kammerer U. Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage. Anticancer Res. 2008; 28; 1719-1724.
13. Lee TH, Seng S, Sekine M et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007; 4; e186.
14. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res. Treat. 2003; 82; 147-154.
15. Kallergi G, Markomanolaki H, Giannoukaraki V et al. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res. 2009; 11; R84.
16. Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr. Relat. Cancer 2006; 13; 905-919.
17. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001; 12; 129-135.
18. Weigand M, Hantel P, Kreienberg R, Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 2005; 8; 197-204.
19. Xie B, Tam NN, Tsao SW, Wong YC. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Br. J. Cancer 1999; 81; 1335-1343.
20. Sini P, Samarzija I, Baffert F et al. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics. Cancer Res. 2008; 68; 1581-1592.
21. Mylona E, Alexandrou P, Giannopoulou I et al. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol. Oncol. 2007; 104; 557-563.
22. Meunier-Carpentier S, Dales JP, Djemli A et al. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int. J. Oncol. 2005; 26; 977-984.
23. Ryden L, Stendahl M, Jonsson H, Emdin S, Bengtsson NO, Landberg G. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res. Treat. 2005; 89; 135-143.
24. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 2008; 26; 4672-4678.
25. Ryden L, Jirstrom K, Bendahl PO et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J. Clin. Oncol. 2005; 23; 4695-4704.
26. Dhakal HP, Naume B, Synnestvedt M et al. Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin. Cancer Res. 2008; 14; 2341-2350.
27. Wiedswang G, Borgen E, Karesen R et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J. Clin. Oncol. 2003; 21; 3469-3478.
28. Naume B, Borgen E, Kvalheim G et al. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin. Cancer Res. 2001; 7; 4122-4129.
29. Ellis IO, Schnitt SJ, Sastre-Garau X et al. Invasive breast carcinoma. In Tavassoli FA, Devilee P eds. World Health Organization classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs. Lyon: IARC Press, 2003; 13-59.
30. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
31. Smith NR, Baker D, James NH et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin. Cancer Res. 2010; 16; 3548-3561.
32. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005; 353; 793-802.
33. Kato T, Kameoka S, Kimura T, Nishikawa T, Kasajima T. Angiogenesis and blood vessel invasion as prognostic indicators for node-negative breast cancer. Breast Cancer Res. Treat. 2001; 65; 203-215.
34. Westenend PJ, Meurs CJ, Damhuis RA. Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J. Clin. Pathol. 2005; 58; 196-201.
35. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat. Rev. Cancer 2004; 4; 448-456.
36. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat. Rev. Cancer 2005; 5; 591-602.
37. Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol. Cancer Res. 2008; 6; 1630-1638.
38. Stewart M, Turley H, Cook N et al. The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology 2003; 43; 33-39.
39. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nor JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010; 17; 499-512.
40. Thor AD, Edgerton SM, Jones FE. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am. J. Pathol. 2009; 175; 1802-1809.
41. Byrnes K, White S, Chu Q et al. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann. Surg. 2006; 243; 684-690.
42. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res. 1997; 57; 3924-3928.
43. Mercurio AM, Lipscomb EA, Bachelder RE. Non-angiogenic functions of VEGF in breast cancer. J. Mammary Gland Biol. Neoplasia 2005; 10; 283-290.
44. O'Reilly MS. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69; S64-S66.
45. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 2010; 10; 130-137.
46. Forero-Torres A, Saleh MN, Galleshaw JA et al. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. Clin. Breast Cancer 2010; 10; 275-280.
47. Hurvitz SA, Allen HJ, Moroose RL et al. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin. Breast Cancer 2010; 10; 307-312.
48. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 2010; 28; 780-787.